1 Ocak 2022 Dergi makalesi Açık Erişim

Kalkanli Tas, Sevgi; Uzunoglu, Merve Saide; Uzunoglu, Aylin Seher; Kirkik, Duygu; Altunkanat, Derya; Kalkanli, Nevin

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
    <subfield code="o">oai:aperta.ulakbim.gov.tr:256005</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">Coronavirus disease 2019 (COVID-19) pandemic has been an important global interest that affected millions of people, and it requires a deep investigation of the disease immunology for developing further therapeutic applications. Adoptive T cell therapy promises to address T cell-dependent immune dysregulation in COVID-19 patients by the generation of specific T cell clones against virus-specific antigens. Additionally, targeting B cell-dependent protection through COVID-19 vaccines, which have been developed in the recent year, possessed sufficient prevention for spreading the virus, since the cases and deaths related to COVID-19 tend to decrease after the vaccination. However, adoptive cell therapies are now encouraging scientists to deal with pathological challenges like inadequate T cell-dependent immune response or lymphopenia, since they are the most frequent outcome of severe infection, especially in immunocompromized patients. In this review, the current knowledge of immunopathology of COVID-19 was aimed to be highlighted along with the T cell responses against SARS-CoV-2 to comprise a basis for therapeutics. Moreover, current therapeutics and treatment strategies for COVID-19 were discussed to evaluate possible agents. Furthermore, the use of adoptive T cell therapy representing an emerging therapeutic approach was purposed to be presented comprehensively against SARS-CoV-2 infection. Even though further studies are needed to fully understand T cell response against SARS-CoV-2 in order to develop therapies to provide long term and efficient protection, adoptive cell therapies now meet the demand for a large population of people who suffer immunocompromization, considering the previous usage of the technique for different infectious diseases.</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Kalkanli Tas, Sevgi</subfield>
    <subfield code="u">Univ Hlth Sci, Hamidiye Med Fac, Dept Immunol, Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="z">md5:cf486be9c11cc4da710884d0728ade80</subfield>
    <subfield code="s">229</subfield>
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/256005/files/bib-3c839f1e-b023-480d-81e7-e3d18071e6b4.txt</subfield>
  </datafield>
  <controlfield tag="005">20230729053746.0</controlfield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2022-01-01</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.55730/1300-0152.2579</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="v">46</subfield>
    <subfield code="p">TURKISH JOURNAL OF BIOLOGY</subfield>
    <subfield code="c">105-117</subfield>
    <subfield code="n">2</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Uzunoglu, Merve Saide</subfield>
    <subfield code="u">Univ Hlth Sci, Hamidiye Inst Hlth Sci, Dept Immunol, Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Uzunoglu, Aylin Seher</subfield>
    <subfield code="u">Univ Hlth Sci, Hamidiye Inst Hlth Sci, Dept Immunol, Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Kirkik, Duygu</subfield>
    <subfield code="u">Univ Hlth Sci, Hamidiye Med Fac, Dept Med Biol, Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Altunkanat, Derya</subfield>
    <subfield code="u">Univ Hlth Sci, Hamidiye Med Fac, Dept Med Biol, Istanbul, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Kalkanli, Nevin</subfield>
    <subfield code="u">Diyarlife Hosp, Dept Dermatol, Diyarbakir, Turkey</subfield>
  </datafield>
  <controlfield tag="001">256005</controlfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
</record>